English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/169182
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Título

Differentiation stage of myeloma plasma cells: Biological and clinical significance

AutorPaiva, Bruno; Puig, Noemi; Cedena, Maria-Teresa; Jong, B. G. de; Ruiz, Y.; Rapado, Inmaculada; Martínez-López, Joaquín; Cordon, Lourdes; Alignani, Diego; Delgado, J. A.; Zelm, Menno C. van; Dongen, J. J. M. van; Pascual, M.; Agirre, X.; Prosper, Felipe; Martín-Subero, J. I.; Vidriales, Maria Belén; Gutiérrez, Norma Carmen; Hernández, M. Teresa ; Oriol, Albert; Echeveste, María-Asunción; Gonzalez, Yolanda; Johnson, S. K.; Epstein, J.; Barlogie, B.; Morgan, Gareth J.; Orfao, Alberto ; Bladé, Joan; Mateos, Maria Victoria; Lahuerta, Juan José; San Miguel, Jesús F.
Fecha de publicación2017
EditorNature Publishing Group
CitaciónLeukemia 31(2): 382-392 (2017)
ResumenThe notion that plasma cells (PCs) are terminally differentiated has prevented intensive research in multiple myeloma (MM) about their phenotypic plasticity and differentiation. Here, we demonstrated in healthy individuals (n=20) that the CD19-CD81 expression axis identifies three bone marrow (BM)PC subsets with distinct age-prevalence, proliferation, replication-history, immunoglobulin-production, and phenotype, consistent with progressively increased differentiation from CD19+CD81+ into CD19-CD81+ and CD19-CD81- BMPCs. Afterwards, we demonstrated in 225 newly diagnosed MM patients that, comparing to normal BMPC counterparts, 59% had fully differentiated (CD19-CD81-) clones, 38% intermediate-differentiated (CD19-CD81+) and 3% less-differentiated (CD19+CD81+) clones. The latter patients had dismal outcome, and PC differentiation emerged as an independent prognostic marker for progression-free (HR: 1.7; P=0.005) and overall survival (HR: 2.1; P=0.006). Longitudinal comparison of diagnostic vs minimal-residual-disease samples (n=40) unraveled that in 20% of patients, less-differentiated PCs subclones become enriched after therapy-induced pressure. We also revealed that CD81 expression is epigenetically regulated, that less-differentiated clonal PCs retain high expression of genes related to preceding B-cell stages (for example: PAX5), and show distinct mutation profile vs fully differentiated PC clones within individual patients. Together, we shed new light into PC plasticity and demonstrated that MM patients harbouring less-differentiated PCs have dismal survival, which might be related to higher chemoresistant potential plus different molecular and genomic profiles.
Versión del editorhttps://doi.org/10.1038/leu.2016.211
URIhttp://hdl.handle.net/10261/169182
Identificadoresdoi: 10.1038/leu.2016.211
e-issn: 1476-5551
issn: 0887-6924
Aparece en las colecciones: (IBMCC) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
diffemyelosig.pdf1,8 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.